Compass Therapeutics earnings were -$55.2M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest CMPX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$16.6M, up 10.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CMPX reported annual earnings of -$49.4M, with 16.2% growth.
Compass Therapeutics Earnings Reports & History FAQ
What were Compass Therapeutics's earnings last quarter?
Compass Therapeutics (NASDAQ: CMPX) reported Q1 2025 earnings per share (EPS) of -$0.12, up 50% year over year. Total CMPX earnings for the quarter were -$16.63 million. In the same quarter last year, Compass Therapeutics's earnings per share (EPS) was -$0.08.
Is Compass Therapeutics profitable or losing money?
As of the last Compass Therapeutics earnings report, Compass Therapeutics is currently losing money. Compass Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$55.22 million, a 21.52% increase year over year.
What was CMPX's earnings growth in the past year?
As of Compass Therapeutics's earnings date in Q2 2025, Compass Therapeutics's earnings has grown year over year. CMPX earnings in the past year totalled -$55.22 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.